Ghiath M. Sukhtian insider trades: Outlook Therapeutics (OTLK) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ghiath reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | OTLK | ↑ Buy | 2,525,252 | $0.99 | $2.5M | Indirect | Aug 14, 2026 (2d) |
| May 28, 2026 | OTLK | ↑ Buy | 8,539,709 | $0.59 | $5.0M | Indirect | Jun 1, 2026 (4d) |
| Nov 29, 2021 | OTLK | ↑ Buy | 16,000,000 | $1.25 | $20.0M | Indirect | Dec 1, 2021 (2d) |
| Feb 2, 2021 | OTLK | ↑ Buy | 8,360,000 | $1.00 | $8.4M | Indirect | Feb 2, 2021 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other OTLK insiders
Open-market trades in the last 12 months
About Ghiath M. Sukhtian's insider trades
Ghiath M. Sukhtian is an insider at Outlook Therapeutics (OTLK). Since Feb 2, 2021, Ghiath has reported 4 open-market purchases worth $35.9M and no sales on SEC Form 4. In the last 12 months: 2 buys ($7.5M).
Their filings also include grants and awards (11 filings), other transactions (9 filings), option exercises (5 filings), shares returned to the company (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OTLK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.